“…At least in small early-experience studies with short-term follow-up, hybrid revascularization appears feasible and safe. [41][42][43] However, an increased need for early antiplatelet therapy with the risk for bleeding complications and repeat revascularization, driven by IR and in-stent restenosis, may reduce the overall benefit. 8,44 In addition, Lichtenberg et al 45 showed that multivessel disease was an independent risk factor for adverse outcome in patients undergoing minimally invasive revascularization of the LAD using the internal thoracic artery (n=149), with, however, acceptable midterm morbidity and mortality.…”